First Posted 2021-10-25 Trial status Active, not recruiting Sponsor Hoffmann-La Roche Abstract Presentation Meeting Abstract: 2025 ASCO Annual Meeting I May 28, 2025 Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Click here for details Peer-reviewed journal publication Efficacy and safety of first-line maintenance t

First Posted 2020-04-17 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Peer-reviewed journal publication Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer J Clin Oncol Sep 2025 PUBMED JCO NCCN FDA NCT04351555: Phase 3: (NeoADAURA): Osimertinib VS Osimertinib + Chemo VS Chemo Alone - Neoadjuvant Therapy - EGFRm Positive Resectable Non-Small Cell Lung Cancer (A Study of Osimertinib With or Without Chemotherapy Versus C